CompletedPhase 2NCT02463409
Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)
Studying Albright hereditary osteodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vanderbilt University Medical Center
- Principal Investigator
- Ashley H Shoemaker, MD, MSCIVanderbilt University
- Intervention
- Theophylline(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 10-21 years · All sexes
- Timeline
- 2015 – 2016
Study locations (1)
- Vanderbilt Unversity, Nashville, Tennessee, United States
Collaborators
Massachusetts General Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02463409 on ClinicalTrials.govOther trials for Albright hereditary osteodystrophy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT04551170Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years OldVanderbilt University Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT03029429Theophylline Treatment for PseudohypoparathyroidismVanderbilt University Medical Center
- RECRUITINGNANCT00209235Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral AssessmentsConnecticut Children's Medical Center